Embotrap
Payments companies reported to CMS as associated with Embotrap. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Embotrap, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Embotrap
These are the largest totals companies reported as associated with Embotrap. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| David Liebeskind | Los Angeles, CA | Neurology (Psychiatry & Neurology) | $684,005.74 |
| Ansaar Rai | Morgantown, WV | Neuroradiology | $33,758.84 |
| Philip Meyers | New York, NY | Vascular & Interventional Radiology | $28,405.84 |
| Osama Zaidat | Toledo, OH | Vascular Neurology | $26,071.88 |
| Mohammad Chaudry | Greenville, SC | Neuroradiology | $25,643.69 |
| Sudhakar Satti | Paoli, PA | Neuroradiology | $25,603.94 |
| Violiza Acosta | Memphis, TN | Vascular Neurology | $22,919.86 |
| Ajay Wakhloo | Worcester, MA | Diagnostic Radiology | $19,288.90 |
| Fawaz Al Mufti | Valhalla, NY | Neurology (Psychiatry & Neurology) | $18,463.90 |
| Jesse Jones | Birmingham, AL | Diagnostic Radiology | $17,237.09 |
Prescribed Embotrap?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.